Armacokinetic profile. Translation in two sophisticated BC individuals, resulted in no unwanted effects, confirming prior observations around the biosafety of radiotracers determined by the potent GRPR-antagonist [DPhe6 ,LeuNHEt13 ]BBN(6-13) and on GRPR-antagonist radioligands in general. Additionally, it revealed the capability of [99m Tc]Tc-DB15 to detect numerous metastatic BC lesions, both within the skeleton and in soft tissues, but these findings must be confirmed prospectively in a dedicated human study. In view of the above, additional clinical evaluation seems to become warranted to establish the diagnostic value of [99m Tc]Tc-DB15 in BC, Pc, as well as other GRPR-expressing human malignancies.Supplementary Materials: The following are readily available on-line at https://www.mdpi.com/article/ ten.3390/cancers13205093/s1, Figure S1: Common radiochromatogram of HPLC analysis of [99m Tc]TcDB15 (preclinical); Figure S2: Typical radiochromatogram of HPLC evaluation of [99m Tc]Tc-DB15 (for individuals); Figure S3: Whole physique scan three h pi of [99m Tc]Tc-DB15 in patient 1 (with anterior and posterior projection); Figure S4: PET/CT 1 h pi of [18 F]FDG in patient 1; Table S1: Numerical biodistribution data for [99m Tc]Tc-DB15 in PC-3 xenograft-bearing SCID mice at 1, 4 and 24 h pi; Table S2: Numerical biodistribution data for [99m Tc]Tc-DB15 in T-47D xenograft-bearing SCID mice at 1, four and 24 h pi.Cancers 2021, 13,12 ofAuthor Contributions: Conceptualization, B.A.N., R.M. and T.M.; methodology, B.A.N., A.K., P.K., B.J., B.B., D.I. and T.M.; validation, B.A.N., R.M., R.C., D.I. and T.M.; investigation, B.A.N., A.K., P.K., B.J., B.B., R.C., D.I. and T.M.; resources, R.M., R.C. and T.M.; information curation, P.K., R.M., R.C. and T.M.; writing–original draft preparation, T.M.; writing–review and editing, all co-authors; supervision, B.A.N., R.M., R.C. and T.M.; project administration, R.M., R.C. and T.M.; funding acquisition, R.M., R.C. and T.M. All authors have read and agreed towards the published version of the manuscript. Funding: The preclinical study was co-financed by Greece and also the European Union (European Regional Development Fund) via the project “NCSRD–INRASTES analysis activities within the framework in the national RIS3” (MIS 5002559), implemented under the “Action for the Strategic Improvement around the Research and Technological Sector”, funded by the Operational Plan “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020). Additional support was offered by Siemens AG via the project stablishing a Multidisciplinary and Efficient Innovation and Entrepreneurship Hub(E-11928). The preparation on the Rigosertib Autophagy radioligand for the patient study was supported by the CERAD project, financed beneath Clever Growth Operational Program 2014020, Priority IV, Measure 4.two. POIR.04.02.004-A001/16. The clinical part of the study obtained monetary help from the Poznan University of Medical Sciences (grant No. 502-14-22213550-41147). Institutional Critique Board Statement: The animal and patient research have been carried out in line with the suggestions in the Declaration of Helsinki. The animal protocols had been approved by the Department of Agriculture and Veterinary Service from the Prefecture of Athens (protocol numbers #1609 for the stability and #1610 for the biodistribution studies, each ML-SA1 Data Sheet issued on 11 April 2018). The patient study protocol was authorized by the Bioethical Committee with the Poznan University of Healthcare Sciences (decision no. 1153 issued on 16 January 2020). Informed Consent Statement: Individuals gave th.
